Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF

Abstract

The CDKN2A gene, which encodes the proteins p16INK4a and p14ARF, is located on chromosome 9p21. Germline mutations at this locus increase susceptibility to cutaneous malignant melanoma (CMM). In general, missense and nonsense mutations are primarily responsible for defective p16INK4a and possibly p14ARF protein function and account for 20% of inherited CMM cases. We report a G>T transversion mutation in the last nucleotide of exon 2, affecting the aspartic acid residue at position 153 of CDKN2A-p16INK4a in a proband with melanoma. If splicing were unaffected, this mutation would change Asp to Tyr. RT–PCR analysis, however, revealed that this mutation, which we have termed D153spl(c.457G>T), and a previously described mutation at the next nucleotide, IVS2+1G>T, result in identical aberrant splicing affecting both p16INK4a and p14ARF. The two main alternate splice products for each of the two normal transcripts includes a 74 bp deletion in exon 2, revealing a cryptic splice site, and the complete skipping of exon 2. The dual inactivation of p16INK4a and p14ARF may contribute to the CMM in these families.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Goldstein AM, Struewing JP, Chidambaram A, Fraser MC and Tucker MA . (2000). J. Natl. Cancer Inst., 92, 1006–1010.

  • Goldstein AM and Tucker MA . (2001). Arch. Dermatol., 137, 1493–1496.

  • Haber DA . (1997). Cell, 91, 555–558.

  • Harland M, Mistry S, Bishop DT and Bishop JA . (2001). Hum. Mol. Genet., 10, 2679–2686.

  • Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WJ, Tucker MA and Dracopoli NC . (1994). Nat. Genet., 8, 15–21.

  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE and Skolnick MH . (1994). Science, 264, 436–440.

  • Kefford RF, Newton Bishop JA, Bergman W and Tucker MA . (1999). J. Clin. Oncol., 17, 3245–3251.

  • Krawczak M, Reiss J and Cooper DN . (1992). Hum Genet, 90, 41–54.

  • Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M and Kern S . (2002). Cancer, 94, 84–96.

  • Moskaluk CA, Hruban H, Lietman A, Smyrk T, Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT and Kern SE . (1998). Hum. Mutat., 12, 70.

  • Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA . (1994). Nature, 368, 753–756.

  • Pesole G, Liuni S, Grillo G, Ippedico M, Larizza A, Makalowski W and Saccone C . (1999). Nucleic Acids Res., 27, 188–191.

  • Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G and Genuardi M . (2001). Genes Chromosomes Cancer, 31, 398–401.

  • Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA . (1998). Cell, 92, 713–723.

  • Quelle DE, Cheng M, Ashmun RA and Sherr CJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 669–673.

  • Quelle DE, Zindy F, Ashmun RA and Sherr CJ . (1995). Cell, 83, 993–1000.

  • Rizos H, Becker TM, Holland EA, Kefford RF and Mann GJ . (1997). Oncogene, 15, 515–523.

  • Rocco JW and Sidransky D . (2001). Exp. Cell Res., 264, 42–55.

  • Serrano M, Hannon GJ and Beach D . (1993). Nature, 366, 704–707.

  • Zhang S, Ramsay ES and Mock BA . (1998). Proc. Natl. Acad. Sci. USA, 95, 2429–2434.

  • Zhang Y and Xiong Y . (1999). Mol. Cell, 3, 579–591.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeffery P Struewing.

Additional information

This article is a ‘United States Government Work’ paper as defined by the US copyright Act

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rutter, J., Goldstein, A., Dávila, M. et al. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene 22, 4444–4448 (2003). https://doi.org/10.1038/sj.onc.1206564

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206564

Keywords

This article is cited by

Search

Quick links